Atea Pharmaceuticals, Inc. Stock Price, News & Analysis

Atea Pharmaceuticals (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET. The presentation will include insights into Atea's focus on developing oral therapeutics for severe viral infections, particularly for ssRNA viruses like SARS-CoV-2, the virus causing COVID-19. A live webcast of the event can be accessed here. A replay will be available for 90 days.

Atea Pharmaceuticals has appointed Jerome Adams, M.D., M.P.H., former U.S. Surgeon General, to its Board of Directors. Dr. Adams brings extensive experience in clinical practice, public health, and leadership roles, particularly during the COVID-19 pandemic. His expertise will support Atea's ongoing global Phase 3 clinical trial for AT-527, an oral antiviral aimed at treating COVID-19. Atea focuses on developing innovative therapies for severe viral infections, leveraging its proprietary nucleotide prodrug platform.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) recently reported its financial results for Q1 2021, highlighting a net income of $30.7 million, a significant turnaround from a net loss of $4.0 million in Q1 2020. The rise was primarily driven by $66.0 million in collaboration revenue from its Roche License Agreement. Atea initiated the global Phase 3 MORNINGSKY trial for AT-527, aimed at treating COVID-19, with expected enrollment of up to 1,400 patients. Additionally, enrollment is advancing for the Phase 1a trial of AT-752 for dengue fever, showcasing Atea's commitment to tackling infectious diseases.

Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call on May 13, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a corporate update. The call will be accessible via a domestic and international dialing option, and an audio webcast will be available on Atea's website. The company focuses on developing antiviral therapies for life-threatening viral diseases, including COVID-19, dengue, hepatitis C, and respiratory syncytial virus, utilizing its proprietary nucleotide prodrug platform.

Atea Pharmaceuticals announced the initiation of the Phase 3 MORNINGSKY trial for AT-527, an oral antiviral aimed at treating mild to moderate COVID-19 in outpatient settings. The trial intends to enroll approximately 1,400 non-hospitalized patients globally, including in Japan. AT-527 targets SARS-CoV-2 RNA polymerase, potentially effective against variants. This trial marks a significant milestone in Atea's collaboration with Roche to develop a widely applicable oral therapeutic against COVID-19.

Atea Pharmaceuticals (Nasdaq: AVIR) reported transformative developments in 2020, bolstered by its antiviral platform against COVID-19. The company advanced its lead candidate, AT-527, entering a strategic partnership with Roche for its development and commercialization. Atea initiated Phase 1a trials for AT-752 to combat dengue fever. Financially, cash reserves soared to $850.1 million from $21.7 million year-over-year, reflecting a net loss reduced to $10.9 million. Collaborations yielded $48.6 million in revenue, demonstrating strong market positioning and ongoing clinical trials aimed at enhancing patient treatment options.

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, will host a conference call on March 30, 2021, at 4:30 p.m. ET to discuss its fourth quarter and full-year financial results for 2020. The event will also provide a business overview. Investors can access the call via phone or a live audio webcast available on Atea's website. Atea focuses on developing therapies for life-threatening viral diseases using a proprietary nucleotide prodrug platform.

Atea Pharmaceuticals (NASDAQ: AVIR) presented promising results from a Phase 1 study of AT-527, an oral antiviral treatment for COVID-19, at the 28th Annual Conference on Retroviruses and Opportunistic Infections. The study confirmed AT-527's favorable pharmacokinetic profile, showing rapid attainment of steady-state levels in healthy volunteers and potential lung exposure exceeding the effective concentration needed to inhibit SARS-CoV-2 replication. The drug was well tolerated, supporting the 550 mg twice-daily dosing for future clinical trials.

Atea Pharmaceuticals has announced that Chugai Pharmaceutical has obtained exclusive rights to develop and market AT-527 for COVID-19 in Japan from Roche. This collaboration emphasizes a commitment to global accessibility for COVID-19 treatments. AT-527, an oral antiviral, is currently in phase 2 trials and aims to reduce disease severity and transmission. The partnership with Roche, established in October 2020, enhances Atea's capacity to accelerate clinical development and provide treatment options quickly.